{"id":"angiogenic-cell-precusors","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"The therapy utilizes patient-derived cells with angiogenic potential to stimulate the formation of new blood vessels in damaged or ischemic tissues. These cells are intended to secrete pro-angiogenic factors and potentially differentiate to support vascular repair and tissue regeneration.","oneSentence":"Autologous cell therapy designed to promote angiogenesis and neovascularization in ischemic tissues."},"_scrapedAt":"2026-03-28T05:55:11.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123576,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"CD34+ cells","brand":null,"company":null,"rationale":"Autologous stem cell therapy for cardiovascular regeneration"},{"name":"Endothelial progenitor cells","brand":null,"company":null,"rationale":"Cell-based angiogenic therapy for ischemic conditions"}],"description":"Angiogenic Cell Precursors is an investigational cell therapy developed by TheraVitae Ltd. The therapy involves autologous cells intended to promote blood vessel formation and tissue regeneration. It is in early-stage clinical development for potential cardiovascular and ischemic conditions.","indications":{"approved":[{"status":"investigational","condition":"Cardiovascular disease","patientPopulation":"Adult"},{"status":"investigational","condition":"Peripheral arterial disease","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT00416663","phase":"PHASE1, PHASE2","title":"Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure","status":"UNKNOWN","sponsor":"TheraVitae Ltd.","startDate":"2007-08","conditions":"Angina Pectoris","enrollment":10},{"nctId":"NCT00523224","phase":"PHASE1","title":"ACPs Combined With CABG in Patients With CHF","status":"UNKNOWN","sponsor":"TheraVitae Ltd.","startDate":"2006-01","conditions":"Congestive Heart Failure","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Angiogenic Cell Precusors","genericName":"Angiogenic Cell Precusors","companyName":"TheraVitae Ltd.","companyId":"theravitae-ltd","firstApprovalDate":"","aiSummary":"Angiogenic Cell Precursors (ACPs) are being studied as a potential treatment for Congestive Heart Failure and Angina Pectoris through intracoronary administration. ACPs are autologous cells, meaning they are derived from the patient's own body, and are administered via a coronary artery bypass grafting (CABG) procedure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}